Zacks.com on MSN20h
IONS’ Better-Than-Expected Q4 ResultsEC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback